Uncategorized
Oral tyrosine kinase inhibitor shows promising early results in AMD patients
Oral pazopanib was well tolerated and may have improved visual acuity and central retinal lesion thickness in patients with neovascular age-related macular degeneration, according to a small study.The analysis comprised data from two studies: a 14-day phase 1 placebo-controlled study with 72 healthy subjects and a 28-day phase 2a open-label study with 15 patients who had subfoveal choroidal neovascularization secondary to AMD.The AMD patients received oral pazopanib 15-mg tablets once daily for 28 days. Healthy subjects received single or repeated oral pazopanib 5-, 10-, 20- or 30-mg tablets or placebo once (Read more...)